Labcorp (NYSE: LH), a global life sciences company has closed its acquisition of Toxikon Corp.

Toxikon is a contract research organization delivering best-in-class nonclinical testing services. The addition of the firm to Labcorp’s drug development segment bolsters its nonclinical development portfolio and creates a strategic footprint for the firm to partner with pharmaceutical and biotechnology clients.

Labcorp provides vital information to assist doctors, hospitals, pharmaceutical companies, patients and more make clear decisions. The firm reported revenues of $14 billion in the 2020 fiscal year.